MedTrace Logo

Clinical Study of Anti-ILT3 CAR-T Therapy for R/R AML(M4/M5)

NCT04803929 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2021-03-23

No results posted yet for this study

Summary

This study evaluates the safety and efficacy of novel ILT3-targeted CAR-T cell therapy for patients with relapsed or refractory acute myeloid leukemia (M4/M5).

Conditions

  • AML M4
  • AML M5

Interventions

BIOLOGICAL

anti-ILT3 CAR-T

Autologous T cells genetically modified with anti-ILT3 CAR

Sponsors & Collaborators

  • Zhejiang Provincial People's Hospital

    collaborator OTHER

  • Carbiogene Therapeutics Co. Ltd.

    lead INDUSTRY

Principal Investigators

  • Jianping Lan · Zhejiang Provincial People's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-03-03
Primary Completion
2024-03-01
Completion
2026-03-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04803929 on ClinicalTrials.gov